Showing results (141-150 of 530) with videos related to
Sort By:
Pageof 53
Clinical Nuclear Medicine|February 3, 2011
C11-acetate and F-18 FDG PET for men with prostate cancer bone metastases: relative findings and response to therapyEvan Y Yu, Mark Muzi, Joy A Hackenbracht, et al.Cancer Research|September 24, 2009
MYC activity mitigates response to rapamycin in prostate cancer through eukaryotic initiation factor 4E-binding protein 1-mediated inhibition of autophagyBala S Balakumaran, Alessandro Porrello, David S Hsu, et al.Journal of the National Comprehensive Cancer Network : JNCCN|September 4, 2020
Complexities of Next-Generation Sequencing in Solid Tumors: Case StudiesAlexandra O Sokolova, Brian H Shirts, Eric Q Konnick, et al.The Prostate|December 20, 2016
Clinical Correlates of Benefit From Radium-223 Therapy in Metastatic Castration Resistant Prostate CancerAjjai Alva, Luke Nordquist, Stephanie Daignault, et al.The Prostate|June 22, 2016
A Pilot Study of Clinical Targeted Next Generation Sequencing for Prostate Cancer: Consequences for Treatment and Genetic CounselingHeather H Cheng, Nola Klemfuss, Bruce Montgomery, et al.Cancer Research|December 22, 2022
Systematic Interrogation of Tumor Cell Resistance to Chimeric Antigen Receptor T-cell Therapy in Pancreatic CancerKimberly R Hagel, Rand Arafeh, Sydney Gang, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 25, 2010
Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancerKim N Chi, Sebastien J Hotte, Evan Y Yu, et al.The Prostate|November 7, 2017
Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancerHeather H Cheng, Melissa Plets, Hongli Li, et al.Prostate Cancer and Prostatic Diseases|February 15, 2020
Survival outcomes and risk group validation from SWOG S0925: a randomized phase II study of cixutumumab in new metastatic hormone-sensitive prostate cancerRisa L Wong, Mai T Duong, Catherine M Tangen, et al.Proceedings of the National Academy of Sciences of the United States of America|November 13, 2013
Synthetic lethality between CCNE1 amplification and loss of BRCA1Dariush Etemadmoghadam, Barbara A Weir, George Au-Yeung, et al.Pageof 53